Craig A. Hurwitz

1 ta ish

Reata Pharmaceuticals (United States)

1. Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group

   Jason N. Berman, Robert B. Gerbing, Todd A. Alonzo +10

   Boshqa20112 iqtibos

   ABIABI:AkademIndex/2026.other.574560